Overview

A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes

Status:
Completed
Trial end date:
2016-07-11
Target enrollment:
Participant gender:
Summary
In period I, the treatment effect of FK949E was compared with that of placebo in a blind manner in bipolar disorder patients with major depressive episodes. In period II, the long-term safety and efficacy of FK949E was evaluated.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Quetiapine Fumarate